
Last Price
52 Week Range
A$1.27 - A$3.37
Next Earnings Date
Feb 25 2026 (Estimate)
Next Earnings Date
Feb 25 2026 (Est.)
Last Price
Market Cap | A$3.18B |
EV | A$3.13B |
Shares Outstanding | 1.34B |
Beta | 0.76 |
Industry | Biotechnology |
Analyst Rating | BUY |
Analyst Target Price | |
Number of Analysts | 4 |
P/E 2026E | 7.40x |
P/Revenue 2026E | 22.42x |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2026E | 85.90% |
Net Profit Margin 2026E | -35.45% |
ROE 2026E | -5.05% |
ROCE 2025 | -18.95% |
DPS 2026E | - |
Payout Ratio 2026E | - |
Div. Yield 2026E | - |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y

Mesoblast Limited
MSB
Sector
Healthcare
Industry
Biotechnology
CEO
Itescu, Silviu
Employees
81
Website
www.mesoblast.comIPO Date
2004-12-15
Headquarters
55 Collins Street, Level 38, Melbourne, Victoria, 3000, Australia
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.